Welcome to our dedicated page for Outlook Therapeutics news (Ticker: OTLK), a resource for investors and traders seeking the latest updates and insights on Outlook Therapeutics stock.
Outlook Therapeutics, Inc. (Nasdaq: OTLK) is a biopharmaceutical company centered on ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma), an ophthalmic formulation of bevacizumab for retina diseases such as wet age-related macular degeneration (wet AMD). News about Outlook Therapeutics typically focuses on clinical, regulatory, and commercial milestones related to this product candidate and its marketed formulation in Europe and the UK.
Readers following OTLK news can expect updates on interactions with the U.S. Food and Drug Administration (FDA), including Biologics License Application (BLA) submissions, complete response letters (CRLs), Type A meetings, and review classifications such as Class 1 reviews with specified PDUFA goal dates. These regulatory developments are central to understanding the potential U.S. path for ONS-5010/LYTENAVA™ as an investigational treatment for wet AMD.
In addition, Outlook Therapeutics issues news on its European and UK activities, including Marketing Authorizations granted by the European Commission and the MHRA, the commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK, and early commercial performance indicators such as initial sales into distribution channels. Company announcements may also cover efforts to expand into additional European markets and explore collaborations with commercial and distribution partners in other regions.
Corporate and financial news items provide insight into Outlook Therapeutics’ leadership changes, strategic hires in areas like corporate strategy and business development, stock-based inducement grants, and periodic financial results that reference revenue from LYTENAVA™ sales and spending patterns related to clinical trials and launches. Conference participation, investor presentations, and scientific meeting appearances are also common topics. For investors and observers interested in the evolution of ophthalmic bevacizumab therapies and wet AMD treatment approaches, the Outlook Therapeutics news feed offers a focused view of the company’s progress.
Outlook Therapeutics has re-submitted its Biologics License Application (BLA) for ONS-5010 to the FDA, aiming to become the first approved ophthalmic formulation of bevacizumab for wet AMD. This follows improvements based on FDA feedback. The company is confident in its submission, citing compelling clinical trial data from the NORSE studies. ONS-5010 demonstrates significant efficacy with 41.7% of patients gaining at least 15 letters of vision. The company is also preparing for a potential 2023 launch by establishing partnerships and building distribution capabilities.
Outlook Therapeutics, Inc. (Nasdaq: OTLK) announced the appointment of Dr. Julia A. Haller to its Board of Directors on August 15, 2022. Dr. Haller, an esteemed ophthalmologist and leader in retinal research, brings extensive experience and expertise, enhancing the company's strategic direction as it advances ONS-5010, an investigational ophthalmic formulation of bevacizumab. This formulation aims to provide FDA-approved treatment options for retinal diseases, addressing the need for safe and effective therapies, particularly for conditions like wet AMD.
Outlook Therapeutics, Inc. (Nasdaq: OTLK) reported a Q3 net loss of $17.5 million, or $0.08 per share, up from a $12.2 million loss last year. The company plans to re-submit its Biologics License Application (BLA) for ONS-5010 by September 2022, following positive FDA feedback. ONS-5010, if approved, would be the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications, addressing the public health risk of off-label usage. The company has $26 million in cash, estimated to fund operations into Q1 2023, and is collaborating with partners for commercial launch preparations.
Outlook Therapeutics (Nasdaq: OTLK) announced that President and CEO Russ Trenary will present at the H.C. Wainwright 2nd Annual Ophthalmology Conference on August 17. This event focuses on the development of ONS-5010/LYTENAVA™, the first FDA-approved ophthalmic formulation of bevacizumab for retinal conditions. Attendees can engage in virtual one-on-one meetings with the management team. A video webcast of the presentation will be available on-demand starting August 17 at 7:00 AM ET on the company's website, archived for 90 days.
Outlook Therapeutics (OTLK) has announced the full cash pre-payment of its unsecured convertible promissory note, dated November 4, 2020, to strengthen its financial position ahead of a potential FDA approval for ONS-5010 (bevacizumab-vikg). The repayment, which eliminates the risk of dilution from converting the note into common stock at a discount, allows the company to maintain investor confidence. The note, which had a face amount of $10,220,000, was initially amended to extend its maturity and increase interest rates, reflecting the company’s focus on upcoming regulatory hurdles.
Outlook Therapeutics (OTLK) has confirmed its plan to re-submit the Biologics License Application (BLA) for its investigational drug ONS-5010 (bevacizumab-vikg) to the FDA by September 2022. This follows a voluntary withdrawal of the original submission in May 2022 to address FDA requests for additional information. The company aims to provide the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications such as wet age-related macular degeneration.
Outlook Therapeutics (OTLK) announced that the FDA has requested more information to complete its Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg) for treating wet age-related macular degeneration. The company voluntarily withdrew the BLA and aims to resubmit a revised application by September 2022. CEO Russell Trenary expressed confidence in the product's potential to be the first FDA-approved ophthalmic formulation of bevacizumab. ONS-5010 is designed to offer a safer alternative to unapproved repackaged formulations used in current treatments for retinal diseases.
Outlook Therapeutics, a pre-commercial biopharmaceutical company, will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami, FL. The company is focused on developing ONS-5010/LYTENAVA™, an investigational therapy aimed at being the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications. The presentation will be led by Lawrence Kenyon, Chief Financial Officer, with opportunities for one-on-one meetings with investors. A video webcast of the presentation will be available on May 24, 2022.
Outlook Therapeutics (Nasdaq: OTLK) has submitted a Biologics License Application (BLA) for ONS-5010, branded as LYTENAVA™, for treating wet age-related macular degeneration (AMD). The company anticipates a PDUFA date announcement in June 2022 and is ramping up pre-launch plans, supported by sufficient funding. Financial results for Q2 2022 show a net loss of $19.7 million, compared to $13.1 million in the previous year, with cash reserves at $58.4 million. Outlook is optimistic about commercial partnerships and aims for global market registration.
Outlook Therapeutics (Nasdaq: OTLK) announced that COO Terry Dagnon will participate in the Retina World Congress 2022 from May 12-15 in Fort Lauderdale, Florida. Dagnon will discuss ONS-5010 (LYTENAVA™), an investigational formulation of bevacizumab for retinal diseases, including wet AMD. The FDA has received a Biologics License Application (BLA) for ONS-5010, which, if approved, would provide 12 years of marketing exclusivity. This product aims to address safety concerns related to off-label IV use of bevacizumab currently prevalent in the retina community.